The Clinical Research Team
Our team consists of a wide range of dedicated professionals from various backgrounds, including nurses, physical therapists, study coordinators, laboratory technicians, research ethics coordinators, and trial finance managers.
Every day, we all work together to find new and better medicines for people living with neurological diseases, all the while producing top-line data for pharmaceutical companies and other research organizations.
CRU Organizational Structure
CRU Executive Director
ANGELA GENGE, M.D., FRCP (c)
Dr. Angela Genge has served as the Medical Director of the Clinical Research Unit (CRU) at the Montreal Neurological Institute since 2004. The CRU develops and executes clinical trials targeting various neurological conditions, with an emphasis on diseases including amyotrophic lateral sclerosis (ALS) neuromuscular diseases and primary brain tumors.
Having participated in landmark clinical trials dating back to 1992, she has developed a particular presence in the multiple sclerosis clinical trial community. The CRU concurrently conducts over 100 clinical trials. Financial sponsors for these trials include industry, government, small biotechnology companies, and private donors. As Medical Director of the CRU, Dr. Genge oversees a team of over 50 coordinators, nurses and support staff, in addition to supporting the Principal Investigators of the Department of Neurology and Neurosurgery of McGill University.
Since 1998, Dr. Genge has been the Director of the ALS Clinic and Research Program. Consisting of 10 multidisciplinary professionals, the ALS clinic at the Neuro provides the finest clinical care for ALS patients and their families. Under Dr. Genge’s direction, the ALS clinical research program develops and tests new ALS therapies. She is working to grow the scope of ALS research through developing novel
Nationally, Dr. Genge is the Chair of the ALS Working Group of the Canadian Neuromuscular Disease Registry (CNDR), and a member of the Governance and Administrative Committee of the new Canadian-Neuromuscular Diseases network. At the Neuro, she is a member of the Neuromuscular Research Group. She is an executive member of the Canadian ALS Research Network (CALS) and a board member of ALS Canada. Internationally, Dr. Genge is an active member of NEALS and WALS, 2 US-based ALS clinical trial networks, and ENCALS in Europe. She is a sought after consultant in clinical trial design for ALS and other orphan neuromuscular diseases. Dr. Genge is particularly interested in collaborating with biotechnology companies who are developing new approaches to manage these currently untreatable conditions.
Dr. Angela Genge is currently an associate professor at McGill University. Dr. Genge earned her medical degree from the Memorial University of Newfoundland. She completed her post-graduate training in Internal Medicine and Neurology, prior to completing a Neuromuscular Disease Fellowship at McGill University. She has recently completed her executive MBA through Lancaster University. Dr. Genge has received numerous awards throughout her career, most recently the DIVA of Distinction Award and the Governor General Diamond Jubilee award. Dr. Genge is also committed to community initiatives which help ALS and neuromuscular patients and their families as well as other groups in need.